ABSTRACT
Article Focus
• PARITY is a multi-center, blinded, randomized controlled trial, using a parallel two-arm design to investigate whether long duration (5 days) postoperative prophylactic antibiotics will decrease the rate of infection compared to short duration (24 hours) among patients undergoing surgical excision and endoprosthetic reconstruction of lower extremity primary bone tumors.
Key Messages
• The immediate goal of PARITY is to provide high quality evidence that can be used in the development of clinical guidelines for antibiotic prophylaxis following tumor excision and endoprosthetic reconstruction of the lower extremity.
• Whereas sarcomas of the long bones are very rare tumors, multi-center international collaboration on a large scale is necessary in order to adequately power any high-quality trials in this field.
• PARITY will mark the first such undertaking, and the rigorous design, organization, and execution of this trial will set a high standand.
Strengths and Limitations
• PARITY will establish a successful network of collaboration from which further high-quality trials in Orthopaedic Oncology will follow.
• The rationale supporting the study design includes demonstrated clinical uncertainly, lack of high-quality evidence, and documented strong investigator support.
• The methodology is supported by tremendous expertise and experience in running large international surgical trials of the Methods Center at the McMaster Center for Evidence-Based Orthopaedics.
• This is a protocol paper. This trial is underway, but has not been completed. 
Magnitude of the Problem
Sarcomas, or malignancies of connective tissue, are a rare form of cancer. These tumors may arise in the long bones of the extremities, and when doing so they often affect adolescents and young adults. Long-bone sarcomas were historically managed with amputations, but the current standard is limb salvage surgery. Limb salvage involves wide tumor resection followed by functional reconstruction. With the aid of modern imaging techniques and chemotherapeutic regimens limb salvage is possible in 95% of patients.
The most common type of functional reconstruction involves the use of tumor endoprostheses. Tumor endoprostheses are modular metallic and polyethylene implants that replace surgically resected bones and joints. Due to the complexity and length of these procedures, as well as the immunocompromised nature of patients treated with chemotherapy, the risk for deep post-operative infection remains high and the outcome can be devastating. 1, 2 These infections require staged endoprosthetic revision surgery and long-term intravenous antibiotic therapy. 3 Even following this management, subsequent repeat infection and ultimate amputation are not uncommon. 1, 4, 5 Patients' function and quality of life are dramatically impacted, as are health care costs. 6 Published guidelines for post-operative antibiotic prophylaxis following many standard elective surgical procedures dictate that prophylactic antibiotics be discontinued after 24 hours. 7 However, the most effective prophylactic antibiotic regimen to prevent deep post-operative infection following surgical excision and endoprosthetic reconstruction of lower extremity bone tumors remains unknown. Current clinical practice is highly varied, particularly with respect to antibiotic duration. Strategies to optimize prevention of these infections while mitigating health care costs are needed.
Best Evidence for Infection Rates
We performed a systematic review to determine reported infection rate outcomes following the treatment of primary long bone tumors (malignant and benign aggressive) by surgical excision and endoprosthetic reconstruction. A systematic literature search of Medline, EMBASE, and the Cochrane database was conducted, and the proceedings of past American Society for Clinical Oncology (ASCO) Annual Meetings were also searched. The search was limited to articles published in English, and no restrictions were placed on dates of publication.
This search generated 3889 titles. In order to minimize bias and ensure that studies were not overlooked, all titles and abstracts were screened by two independent reviewers. Those papers reporting outcomes of endoprosthetic reconstruction in the treatment of malignant or benign aggressive long bone tumors were selected for review. Studies reporting on the use of allografts or allograft-prosthesis composites were excluded. Studies investigating soft-tissue sarcomas, metastatic lesions, recurrent lesions, or lesions that had received prior surgical treatment were excluded. The reported infection rates were extracted from the remaining papers and compared. Both reviewers performed data extraction and assessment of data quality independently, and differences were reconciled by mutual agreement or an independent third party.
Of the 3889 titles, there were 48 eligible studies ( Table 1) . The deep infection rates ranged from 0% to 22.2%, with a weighted mean of 9.5% (95% confidence interval: 8.1% to 11.0%). Duration of antibiotic prophylaxis was reported inconsistently, but ranged from 'intra-operative dosing only' to 'greater than 72 hours'. Two main factors in the development of antibiotic resistance are antibiotic misuse and overuse. 9 Antibiotic misuse is the selection of antibmicrobial agents with inappropriately broad spectrums of efficacy, and antibiotic overuse is an inappropriately excessive frequency or duration of antibiotic prescription. Whereas increasing antibiotic resistance has the potential to significantly impair management of patients with infected endoprostheses, an Evidence-Based approach to antibiotic use is critical.
Other important complications of antibiotic overuse include the development of clostridium difficile-associated colitis and life-threatening toxic megacolon, opportunistic fungal infections, indwelling-catheter related sepsis, and seizures.
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Lack of Consensus in Antibiotic Regimens and Global Interest in an RCT
We conducted a survey addressing the practices of Orthopaedic Oncologists registered with the Musculoskeletal Tumor Society (MSTS) and the Canadian Orthopaedic Oncology Society (CANOOS). 15 From this survey, we concluded that there are currently no guidelines for the prescription of prophylactic antibiotics in musculoskeletal tumor surgery, and that current opinion and practice are highly varied. excision and endoprosthetic reconstruction; 2) a lack of high-level RCT evidence to guide prescription of prophylactic antibiotic regimens; 3) highly-variable opinion and practice regarding prophylactic antibiotic regimens among Orthopaedic Oncologists; and 4) extensive investigator support for a definitive large RCT. 61 These findings provide a strong rationale for undertaking a definitive RCT. The direct potential clinical implications of this work include both fewer endoprosthetic infections and fewer antibiotic related complications.
STUDY DESIGN
Overview of Study Design
PARITY is a multi-center, blinded, randomized controlled trial, using a parallel two-arm design to investigate whether long duration (5 days) postoperative prophylactic antibiotics will decrease the rate of infection compared to short duration (24 hours) among patients undergoing surgical excision and endoprosthetic reconstruction of lower extremity primary bone tumors. Randomization will be stratified by study center and tumor location (femur vs. tibia). Patient enrolment will occur over approximately 1 year and enrolled patients will be followed for 1 year postoperatively. Infection rates will be assessed within 12 months after initial surgery across both study arms. Patient function and quality of life will be assessed preoperatively and at 3, 6, and 12 months postoperatively. Trial conduct procedure is shown in Figure 1 . This trial is registered [NCT01479283] and has received ethics approval from the McMaster University / Hamilton Health Sciences Research Ethics Board (REB# 12-009).
Research Questions
Do long duration prophylactic antibiotics following surgical excision and endoprosthetic reconstruction of lower extremity bone tumors lead to decreased rates of post-operative deep infections in comparison to short duration prophylactic antibiotics? Are there any differences in frequency or type of antibiotic-related adverse events between long and short duration prophylactic antibiotics? Are there any differences in patient functional outcome scores and quality of life scores between long and short duration antibiotics? Are there any differences in occurrence of adverse events, serious adverse events, infections other than deep surgical site infections, complications of wound healing, or tumor recurrence or metastases between long and short duration prophylactic antibiotics?
Hypothesis As a primary outcome, there will be significantly fewer deep post-operative infections and no significant increase in frequency or severity of antibiotic-related complications associated with long duration in comparison to short duration prophylactic antibiotics. As secondary outcomes, we expect no differences in patient functional outcome scores, quality of life scores, adverse events, serious adverse events, infections other than deep surgical site infections, complications of wound healing, or tumor recurrence or metastases between long and short duration prophylactic antibiotics. This study is powered to address the primary outcome, but not the secondary outcomes.
Eligibility Criteria
Inclusion Criteria Men and women of 15 years of age or older who meet all of the following eligibility criteria will be included in the study:
1) Diagnosis of primary malignant or benign aggressive bone tumor of the lower extremity 2) Planned treatment of surgical excision and endoprosthetic reconstruction 3) Provision of informed consent
Exclusion Criteria
Patients who meet any one or more of the following will be excluded from the study: 
Recruitment and Screening
Each clinical site will have a locally responsible investigator that will oversee local administration of the trial. The treating physicians, investigators, study coordinators, and/or their delegates at each site will identify potentially eligible patients upon presentation with a lower extremity bone tumor requiring surgical excision and endoprosthetic reconstruction. All potentially eligible patients will be screened and documented as: 1) eligible and included, 2) eligible and missed, and 3) excluded. The study coordinator or designee will obtain informed consent for participation in the study using local IRB/REB approved Informed Consent forms. Consent will be obtained at the final pre-operative visit 1-2 weeks prior to the anticipated date of the surgery and at the same time that consent is obtained for the procedure. Baseline characteristics forms and preoperative MSTS and TESS questionnaires will be completed at the time of consent.
Allocation of Patients to Study Groups
Patients will be randomized to either short or long duration prophylactic antibiotics only after patient eligibility is established and patient consent is obtained. Actual randomization will occur during surgery, prior to case completion and will be carried out by the pharmacy technician using an internet-based randomization system that ensures concealment. The pharmacy will be notified of upcoming study participants both at the time of consent and on the morning of surgery. Random permuted blocks with varying block sizes of two or four will be utilized, and patients will be the unit of randomization. Randomization will be stratified for the following variables: 1) location of tumor (femur vs. tibia), and 2) study center.
Study Interventions
Surgical excision and endoprosthetic reconstructions will be performed according to the standard practice of the participating surgeons. This typically involves a wide extensile surgical exposure, isolation and protection of major neurovascular structures, resection of the segment of bone affected by tumor with a 2-3 cm bone margin, and a softtissue margin dictated by the amount of available tissue that can be safely resected from both oncological and functional standpoints. Endoprostheses may be implanted with either press-fit or cemented techniques. Soft-tissue reconstruction may or not may not require tissue transfer based on the original extent of the tumor and required softtissue excision to establish wide oncological margins.
Tumor Characteristics Forms, Surgical Report Forms, Peri-operative Forms, and Antibiotics Logs will be completed at the time of surgery, and patients will be assessed for adverse events and protocol deviations in the peri-operative period. All patients will receive 2g of intravenous Ancef® preoperatively and every 3-4 hours intraoperatively.
Short Duration Antibiotics
Patients randomized to the short duration regimen will receive 2g of intravenous Ancef® postoperatively every 8 hours for 24 hours, followed by intravenous 'sham' antibiotics (normal saline) for an additional 4 days.
Long Duration Antibiotics
Patients randomized to the long duration regimen will receive 2g of intravenous Ancef® postoperatively every 8 hours over a 5 day period (maximum), or until hospital discharge if acute care stay is less than 5 days.
Blinding
All antibiotic bags will be identically shrouded. No other antibiotics will be administered for infection prophylaxis. Patients, surgeons, nurses, research personnel, data analysts, and the Central Adjudication Committee (CAC) will be blinded to the antibiotic regimen. The pharmacy technician preparing and shrouding the solutions will not be blinded.
Outcome Measures Primary Outcome
The primary study outcome will be rates of deep post-operative infections in each of the study arms. The CDC definition of a deep surgical site infection (below) will be employed (http://www.cdc.gov/nhsn/PDFs/pscManual/9pscSSIcurrent.pdf). Patients will be monitored regularly for this outcome by their treating physicians at 2 and 4 weeks, and 3, 6, and 9 months, and 1 year post-operatively. If deep infection does occur, the causative organism will be determined and documented.
The CDC criteria we will use defines infection as follows: The infection occurs within 30 days after the operative procedure or within 1 year if an implant is in place and the infection appears to be related to the operative procedure. The infection may involve any part of the body, excluding the skin incision, fascia, or muscle layers, that is opened or manipulated during the operative procedure. The patient must have at least 1 of the following:
1. Purulent drainage from a drain that is placed through a stab wound into the organ/space 2. Organisms isolated from an aseptically obtained culture of fluid or tissue in the organ/space 3. An abscess or other evidence of infection involving the organ/space that is found on direct examination, during reoperation, or by histopathologic or radiologic examination 4. Diagnosis of an organ/space SSI by a surgeon or attending physician.
Secondary Outcomes: The secondary study outcomes include type and frequency of antibiotic-related adverse events, patient functional outcome scores, and patient quality of life scores. We will also evaluate for occurrence of adverse events, serious adverse events, infections other than deep surgical site infections, complications of wound healing, and incidence of tumor recurrence or metastasis. As noted in Figure 1 , the Musculoskeletal Tumor Society functional score (MSTS) (clinician administered) and the Toronto Extremity Salvage Score (TESS) (patient administered) questionnaires will be used to assess functional outcomes prior to surgery, as well as at the 6 month and 1 year follow-up visits. The MSTS and TESS instruments are based on validated, well-accepted functional scoring systems in Orthopaedic Oncology publications. [16] [17] [18] Adjudication of Outcomes A blinded Central Adjudication Committee (CAC) will adjudicate all occurrences of deep surgical site infection and any other instances that may require adjudication. These may include: occurrence of an antibiotic-related complication, occurrence of an infection other than a deep surgical site infection, occurrence of an adverse event or serious adverse event, complications of wound healing, oncological outcomes such as recurrence or metastasis, doubt of eligibility, occurrence of crossover, loss to follow-up, or deviation from protocol. The CAC will be comprised of 3 Orthopaedic Surgeons and 1 Infectious Diseases specialist, and the Global Adjudicator™ web-based platform will used.
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Patient Follow Up
Patients will be assessed at the time of regular follow-up by their treating physician at 2 and 6 weeks, and 3, 6, and 9 months, and 1 year post-operatively. Patients will be assessed for infections (surgical site and other), antibioticrelated complications, adverse events, serious adverse events, complications of wound healing, oncologic outcomes such as local recurrence and metastasis, and protocol deviations. Accompanying forms will be completed as scheduled on Figure 1 . A Missed Follow-Up Form will be completed if a patient misses a follow-up visit. An Early Withdrawal Form will be completed only if a patient withdraws their consent. 
Maximization of Follow-up
Given the malignant potential and patient concern associated with long bone sarcomas, we anticipate only minimal losses to follow-up in our Orthopaedic Oncology population. Nonetheless, the following procedures will be implemented to minimize losses 20 1) Exclusion of individuals who are likely to present difficulty with follow-up (see exclusion criteria); 2) At the baseline assessment, each patient shall provide their own address and phone number, the name and address of their primary care physician, and the name, address and phone number of three people at different addresses with whom the patient did not live who were likely to be aware of the patient's whereabouts; 3) Patients will receive reminders for upcoming clinic visits from the study coordinators; 4) Follow up schedules will coincide with normal post-operative clinic visits; 5) If a patient refuses to return for a follow up assessment, his/her status with regard to the primary and secondary outcomes will be assessed as much as possible by telephone contact with the patient, alternate contact, or their family physician.
Minimization of Crossovers
Crossovers are extremely unlikely between the short and long duration antibiotic regimens given that patients will be blinded and acute infections are unlikely to be recognized in the first 5 days after surgery. Any patients who do crossover will be analyzed in the group to which they were originally allocated, maintaining an 'intention to treat' analysis. Standardization of antibiotic regimens will limit co-intervention, and concurrent use of drugs that affect antibiotic metabolism will be documented. Any procedures that patients undergo while in hospital and any other infections that occur (urinary tract, Port or PICC line) will also be documented.
Sample Size Consideration
The sample size calculation for the definitive trial is based upon a between-groups comparison for the primary outcome of deep infection following long (experimental) or short (control) duration antibiotics. Based on our survey of Orthopaedic Oncologists, we will set a threshold of an absolute difference of 5% to define inferiority. Survey responses indicated that infection rates within less than 5% of each other would not be considered different. 15 Given this information, we will power the study to have sufficient power to detect a between-groups difference of 5%. As identified by our systematic review, infection rates after surgical excision and endoprosthetic reconstruction of bone tumors range from 0-22% with a weighted mean of 9.5% (95% confidence interval: 8.1% to 11.0%) (hence variation in the rate of infection in the control group from 7% to 15%). According to our power After adjustments for potential losses to follow up, errors in eligibility, and study drop outs (approximately 5% total), the total sample requirement [n_adjusted = n/(1-0.05) where n is the calculated sample size] will be 908 patients (454 patients per arm). 
Data Analysis Plan
The results of patient demographics and baseline characteristics will be summarized using descriptive summary measures: expressed as mean (standard deviation) or median (minimum-maximum) for continuous variables and number (percent) for categorical variables. The analysis and reporting of the results of the clinical outcomes with follow the CONSORT guidelines (www.consort-statement.org). Infection rates and secondary outcomes will undergo an intention-to-treat analysis. We will also use multiple-imputation to handle missing data. 21 Proportions of infection in each arm will be compared using Fisher's Exact Tests. Estimates of treatment effects will be reported as relative risks (RR) with corresponding 95% CI and associated p-values. P-values will be reported to three decimal places with values less than 0.001 reported as <0.001. All statistical tests will be performed using two-sided tests at the 0.05 level of significance. We will conduct a multiple regression model to determine if total operative time, tumor location, chemotherapy regimen, diabetes, smoking or other factors are related to infection rates. We will also conduct subgroup analyses for infection rates within each type of tumor (Ewing's, Osteosarcoma, Chondrosarcoma, Giant Cell Tumor) and tumor location (proximal femur, distal femur and proximal tibia). Our a priori hypothesis, based on retrospective data, is that reconstructions of the proximal tibia and tumors that have been treated with neoadjuvant or adjuvant chemotherapy (Ewing's Sarcoma and Osteosarcoma) will be at higher risk for deep infection based on difficulty with soft-tissue coverage in the tibia and the immunocompromised nature of patients on chemotherapy. However, if these subgroup analyses are underpowered, the subgroup data will be used to generate further hypotheses that can be tested in future trials. 22, 23 All analyses will be performed using SAS 9.2 (Cary, NC).
Data Monitoring Committee (DMC)
The DMC will be established at the onset of the trial to monitor the trial and review the study bi-annual progress report. 22, 23 The Committee members will be independent of the trial, free of conflicts with any of the investigative team and will consist of Orthopaedic Surgeons. extremity. More broadly, PARITY will establish a successful network of collaboration from which further highquality trials in Orthopaedic Oncology will follow. Whereas sarcomas of the long bones are very rare tumors, multicenter international collaboration on a large scale is necessary in order to adequately power any high-quality trials in this field. PARITY will mark the first such undertaking, and the rigorous design, organization, and execution of this trial will set a high standand. In so doing, PARITY will lead to the development of Evidence-Based clinical guidelines and impact an entire field.
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